# Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers

> **NCT04114461** · PHASE1 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** HL-TOF tab. 5mg
- **DRUG:** Xeljanz tab. 5mg

## Key facts

- **NCT ID:** NCT04114461
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-06
- **Primary completion:** 2019-12-04
- **Final completion:** 2019-12-04
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04114461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04114461, "Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04114461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*